Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Peijia Medical Ltd. ( (HK:9996) ) just unveiled an announcement.
Peijia Medical Limited reported that its chairman, chief executive officer and executive director, Dr. Yi Zhang, plans to increase his stake in the company by purchasing shares on the open market through a controlled corporation starting March 26, 2026. The planned share purchases will have a total consideration not exceeding HK$15 million and will be executed in compliance with applicable laws and regulations.
According to the company, Dr. Zhang views the additional investment as a demonstration of his confidence in Peijia Medical’s intrinsic value, development prospects and growth potential, and he may further increase his holdings in future. The company also stressed that, even after the shareholding increase, it continues to maintain sufficient public float under Hong Kong listing rules and advised shareholders and potential investors to exercise caution when trading its shares.
The most recent analyst rating on (HK:9996) stock is a Hold with a HK$6.50 price target. To see the full list of analyst forecasts on Peijia Medical Ltd. stock, see the HK:9996 Stock Forecast page.
More about Peijia Medical Ltd.
Peijia Medical Limited is a Hong Kong-listed medical company focused on developing and commercializing healthcare products and technologies. The group operates through its subsidiaries and is led by executive director and chief executive officer Dr. Yi Zhang, who also serves as chairman of the board of directors.
Average Trading Volume: 915,893
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.73B
For a thorough assessment of 9996 stock, go to TipRanks’ Stock Analysis page.